Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

A legfontosabb adatok

Ki végzi
Biomedical Advanced Research and Development Authority
Hol
Atlanta, Austin, Cary, Cincinnati, Conroe, Hickory, Lenexa, Lexington, New Orleans, New York, Oak Lawn, Prairieville, San Antonio, Savannah, Statesville, Sterling, Tulsa, Wichita, Wilmington és Yukon (Egyesült Államok)Mind a 20 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
1380 fő vett részt
Kezdés
2024. aug. 21.
Befejezés
2025. jún. 11.
A vizsgálat típusa
Beavatkozással járó, 15 csoport
A vizsgált kezelések
  • 3.75 µg H5N8 antigen plus full dose AS03A
  • 7.5 µg H5N8 antigen plus full dose AS03A
  • 15 µg H5N8 antigen plus full dose AS03A
  • 3.75 µg H5N8 antigen plus half dose AS03A
  • 7.5 µg H5N8 antigen plus half dose AS03A
  • 15 µg H5N8 antigen plus half dose AS03A
  • 3.75 µg H5N8 antigen plus MF59
  • 7.5 µg H5N8 antigen plus MF59
  • 15 µg H5N8 antigen plus MF59
  • 3.75 µg H5N1 antigen plus full dose AS03A
  • 7.5 µg H5N1 antigen plus full dose AS03A
  • 15 µg H5N1 antigen plus full dose AS03A
  • 3.75 µg H5N1 antigen plus MF59
  • 7.5 µg H5N1 antigen plus MF59
  • 15 µg H5N1 antigen plus MF59
A regiszteradat frissítve
2026. október 1.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or non-pregnant female, 18 years of age or older at the time of screening and informed consent
  • Willing and able to provide written informed consent prior to initiation of study procedures
  • Agrees to have specimens collected during this trial specifically for the purpose of future research stored for future research use
  • In relatively stable health, as determined by medical history and physical examination; Any chronic medical diagnoses or conditions should be stable and well managed, with no significant changes expected during the study period, and in the opinion of the site investigator, will not impact the ability to assess safety and/or immunogenicity per the study design
  • If a female of childbearing potential who is sexually active, agrees to use an adequate method of birth control from Screening through 4 weeks following the last study vaccination and has used an adequate birth control method for at least 2 months prior to Screening; Female of childbearing potential is defined as post onset menarche and pre-menopausal person capable of becoming pregnant. This does not include females who meet any of the following conditions:; menopausal >2 years; tubal ligation >1 year; bilateral salpingo-oophorectomy; hysterectomy; Adequate contraception is defined as a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label, for example: oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; the female participant has exclusively female sexual partners; male partner is sterile or otherwise unable to produce sperm (information on the person's sterility can come from the site personnel's review of the participant's medical records or interview with the participant regarding her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); or male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository)
  • Available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study

Ki nem vehet részt

  • Has an acute illness, as determined by the site investigator, within 72 hours prior to vaccination; An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol
  • Has a history of any pIMDs (list provided in Protocol Appendix 3), neuralgia, paresthesia, neuritis, convulsions, or encephalomyelitis within 90 days prior to Screening, or a family history of Guillain-Barré syndrome
  • Has a history of alcohol or drug abuse within 5 years prior to Screening
  • Has long-term use (≥14 consecutive days) of glucocorticoids including oral or parenteral prednisone or prednisone equivalent (>20 mg total dose per day) or high-dose inhaled steroids (>800 µg/day of beclomethasone dipropionate or equivalent) within 1 month prior to screening in this study. However, participants on low-dose inhaled steroids (≤800 µg/day of beclomethasone dipropionate or equivalent) or topical steroids are not excluded
  • Has received immunoglobulin or other blood product (with the exception of Rho[D] immune globulin) within the 90 days prior to screening in this study
  • Has received any (licensed or under Emergency Use Authorization [EUA]) live vaccines within 4 weeks or inactivated, messenger RNA (mRNA), or recombinant protein vaccines within 2 weeks prior to screening, or plans to receive such vaccines (including seasonal influenza and COVID-19 vaccines) from screening through 22 days following the second dose of the study vaccine, inclusive of the vaccination day (Screening Visit through Day 43)
  • Has participated in an A(H5) influenza vaccine study in the past or has a history of A(H5) influenza infection prior to vaccination in this study. This includes, but is not limited to, influenza sub-types A(H5N1), A(H5N8), and A(H5N6)
  • Has a history of severe reaction to any influenza vaccine
  • Has a known allergy to squalene-based adjuvants
  • Has known human immunodeficiency virus, hepatitis B, or hepatitis C infection (based on medical history)
  • Has any diagnosis, current or past, of schizophrenia, bipolar disease, or any other psychiatric diagnosis that may, in the opinion of the site investigator, interfere with participant compliance or safety evaluations
  • Is immunosuppressed due to an underlying disease or medication, use of anticancer chemotherapy (cytotoxic), or radiation therapy
  • With the exception of basal or squamous cell skin cancer, has known active neoplastic disease, including hematologic malignancy
  • Has any disease or medical condition that, in the opinion of the site investigator, might confound interpretation of safety or immunogenicity
  • Has any laboratory test result or clinical findings (including vital signs) that singly or in combination are likely to unfavorably alter the risks of participant participation or to confound study safety or immunogenicity results, in the opinion of the site investigator. Additionally, the following are exclusionary:; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN), or; Bilirubin >1.5 times the ULN unless isolated Gilbert's syndrome
  • Female of childbearing potential who has a positive urine pregnancy test or who is currently breastfeeding
  • Has a body mass index >35 kg/m2
  • Has narcolepsy or a first degree relative with narcolepsy
  • Is participating or plans to participate in another interventional clinical trial (either active or follow-up phase) during the study period

Helyszínek itt: Egyesült Államok

  • DelRicht Research - AtlantaAtlanta, Egyesült Államok
  • Tekton Research - AustinAustin, Egyesült Államok
  • Accellacare - CaryCary, Egyesült Államok
  • CTI Clinical Research CenterCincinnati, Egyesült Államok
  • Javara Research - Privia Medical Group Gulf CoastConroe, Egyesült Államok
  • Accellacare of HickoryHickory, Egyesült Államok
  • Johnson County Clin-Trials (JCCT)Lenexa, Egyesült Államok
  • Alliance for Multispecialty Research - LexingtonLexington, Egyesült Államok
  • DelRicht Research - New Orleans - Prytania StreetNew Orleans, Egyesült Államok
  • Rochester Clinical ResearchNew York, Egyesült Államok
  • Accellacare - Duly Health and Care - Oak LawnOak Lawn, Egyesült Államok
  • DelRicht Research - PrairievillePrairieville, Egyesült Államok
  • Tekton Research - San AntonioSan Antonio, Egyesült Államok
  • Javara Research - Privia Medical Group GeorgiaSavannah, Egyesült Államok
  • Accellacare - Piedmont HealthcareStatesville, Egyesült Államok
  • DelRicht Research - VirginaSterling, Egyesült Államok
  • DelRicht Research - TulsaTulsa, Egyesült Államok
  • Alliance for Multispecialty Research - Wichita East - Heartland Research AssociatesWichita, Egyesült Államok
  • Accellacare - Tradd CourtWilmington, Egyesült Államok
  • Tekton Research - Oklahoma - Primary Health PartnersYukon, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenza vaccines at different antigen dose levels adjuvanted with AS03 or MF59.

A vizsgálat 15 csoportja

  • Treatment Group AA vizsgált kezelés

    This treatment group of 60 participants (ages 18-64) in Treatment Group A will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) antigen adjuvanted with a full dose of AS03A.

    Kezelés: 3.75 µg H5N8 antigen plus full dose AS03A

  • Treatment Group BA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants ages ≥65) in Treatment Group B will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a full dose of AS03A.

    Kezelés: 7.5 µg H5N8 antigen plus full dose AS03A

  • Treatment Group CA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a full dose of AS03A.

    Kezelés: 15 µg H5N8 antigen plus full dose AS03A

  • Treatment Group DA vizsgált kezelés

    This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.

    Kezelés: 3.75 µg H5N8 antigen plus half dose AS03A

  • Treatment Group EA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.

    Kezelés: 7.5 µg H5N8 antigen plus half dose AS03A

  • Treatment Group FA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65 will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.

    Kezelés: 15 µg H5N8 antigen plus half dose AS03A

  • Treatment Group GA vizsgált kezelés

    This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.

    Kezelés: 3.75 µg H5N8 antigen plus MF59

  • Treatment Group HA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.

    Kezelés: 7.5 µg H5N8 antigen plus MF59

  • Treatment Group IA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.

    Kezelés: 15 µg H5N8 antigen plus MF59

  • Treatment Group JA vizsgált kezelés

    This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.

    Kezelés: 3.75 µg H5N1 antigen plus full dose AS03A

  • Treatment Group KA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.

    Kezelés: 7.5 µg H5N1 antigen plus full dose AS03A

  • Treatment Group LA vizsgált kezelés

    This treatment group of 60 participants (ages ≥65) will receive 15 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.

    Kezelés: 15 µg H5N1 antigen plus full dose AS03A

  • Treatment Group MA vizsgált kezelés

    This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.

    Kezelés: 3.75 µg H5N1 antigen plus MF59

  • Treatment Group NA vizsgált kezelés

    This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.

    Kezelés: 7.5 µg H5N1 antigen plus MF59

  • Treatment Group OA vizsgált kezelés

    This treatment group of 60 participants (age ≥65) will receive 15 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.

    Kezelés: 15 µg H5N1 antigen plus MF59

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03® or MF59®
A regiszteradat frissítve
2026. október 1.